- Home
- LXEO vs MTLS Comparison
LXEO vs MTLS Comparison
Compare LXEO & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | MTLS |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | Computer Software: Prepackaged Software |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.8M | 317.9M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LXEO | MTLS |
|---|---|---|
| Price | $5.16 | $6.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.44 | N/A |
| AVG Volume (30 Days) | ★ 667.0K | 128.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | $6.38 |
| Revenue Next Year | N/A | $6.45 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $4.78 |
| 52 Week High | $10.99 | $6.80 |
Technical Indicators
Market Signals| Indicator | LXEO | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 75.33 |
| Support Level | $4.95 | $5.38 |
| Resistance Level | $6.26 | $6.80 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 36.34 | 97.83 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
About MTLS Materialise NV
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.